Corcept develops cortisol modulators, drugs that act on the glucocorticoid receptor to regulate metabolism, blood pressure and inflammation.
Current Cash Cow
Korlym has been FDA approved since 2012 and is the standard of care for patients with Cushing’s syndrome who also have type 2 diabetes or glucose intolerance. It generates about $850–900 million annually and provides steady positive cash flow that funds R&D and new trials.
The Next Generation
The company’s key growth driver is Relacorilant, a next-gen cortisol modulator. Unlike Korlym, it does not bind the progesterone receptor, giving it a safer profile and the chance to reach more patients. Relacorilant is positioned to expand the market and over time partly replace Korlym.
Key Catalysts
- Dec 30, 2025 – PDUFA for Cushing’s syndrome, peak sales estimated at $3–5 billion
- Jul 11, 2026 – PDUFA for platinum-resistant ovarian cancer, NDA already filed, multi-billion potential
Leadership
Founder and CEO Joseph Belanoff has led the company since 1999 and holds over $200 million in stock, showing strong insider alignment.
My Move
CORT is profitable today with Korlym as the foundation. Relacorilant is the upgrade that could redefine the standard of care and drive much larger sales. With two FDA decisions in the next 18 months, I hold small position in CORT as a high-conviction growth and catalyst play.